Konno K, Akasaka M, Koshida C, Katayama N, Osada N, Spake R, et al
August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone
Demographics of GLP-1 Users Women comprise roughly 6065% of GLP-1 users, driven by higher obesity prevalence and greater engagement with preventive health strategies
Overeating After Appetite Returns Some individuals may overeat when hunger briefly returns, offsetting progress
Clinician guidance helps tailor these strategies based on individual treatment response
5 DIAGNOSIS The use of diagnostic testing is controversial because the etiology of thrombosis is multifactorial and the identification of a thrombophilic defect is only one of many elements that play a role in determining a patients risk